ATANIS Biotech completes capital increase to improve the diagnosis of allergies
ATANIS Biotech aims to simplify and improve the current standard of care for the diagnosis of allergies. With proceeds from the financing, ATANIS will accelerate its product development, scale its services for pharma/biotech customers, and implement its go-to-market strategy.
ATANIS is developing its FAST-PASE technology, offering lab testing solutions to mimic allergic reactions safely in a test tube. Currently, the company is mainly serving customers with needs in preclinical drug development and QC testing.Customers include companies such as CSL Behring, Octapharma or Mabylon. The customer base ranges from highly established industrial partners to individual research groups.
In March, ATANIS moved its operational premises to a new location in Bern enabling the company to increase its sample processing capacity. Additionally, three new team members were appointed, bolstering their commercialization capabilities: Doris Corpataux will lead the company’s regulatory strategy, Nathan Laborde will be responsible for implementing quality processes, and Bertrand Landel will spearhead commercial and marketing operations.
The company has now completed a significant capital increase. iXLife a venture capital fund from France co-led the round with US-based AllerFund, the first and only venture capital firm focused on social impact in the food allergy space. Additional investments came from experienced private biotech investors.
“At ATANIS, our mission is to revolutionize the way allergies are diagnosed and thereby improve treatment success and quality of life for patients,” said Chief Executive Officer Jean-Pierre Kinet, M.D. “With this funding, we look forward to taking the next steps towards bringing our products to the market and making them available to clinicians.”
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines